Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2003

View Archived Issues

Four series of antiangiogenic peptides described by Abbott scientists

Merck claims novel tyrosine kinase inhibitors for use in cancer and other disorders

New PTP inhibitors prepared and tested at Applied Research Systems

Neurotrophic and neuroprotective agents identified by Toyama researchers

New HCV NS5B polymerase inhibitors in GSK development pipeline

Inhibitors of IKK2 and potential uses described in recent patent

New adenosine antagonists with utility in constipation, IBS, etc., covered by Eisai patent

Selenium reduces the risk of progression toward cancer in patients with Barrett's esophagus

Initial phase III results for canker sore treatment OraDisc A

Generex schedules Canadian phase IIb trials of Oralin

Cellegy appoints Neopharm to distribute Tostrex in Israel

Femara increases survival in advanced breast cancer

Fuzeon approved in E.U.

NM-702 enters late phase II trial for chronic arterial occlusion

DB-289 enters phase IIb PCP trial

Results for Thalomid and IMiDs in all stages of multiple myeloma

Arimidex evaluated in women at high risk for breast cancer, very early breast cancer

IND filed for Corus-1020, first patient enrolled in cystic fibrosis study

Orphan drug status awarded to KSB-303 for pancreatic cancer

Medarex reports preclinical results for anthrax antibody

Lilly terminates licensing agreement with Ono

PT-100 shows promise in chemotherapy-induced neutropenia

IND cleared for VaxGen's anthrax vaccine

Protherics intends to acquire Enact

Preliminary evaluation of novel 5-HT2B antagonist indicates potential in IBS

Prous Science announces the publication of a comprehensive review on SARS

Selective eradication of H. pylori with BYK-170424

Inotek advances orally active PARP inhibitor through clinical trials

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026